Kairon Labs and Solidus Labs Partner to Redefine Ethical Market Making Under MiCA
Kairon Labs, a leading crypto market maker and liquidity provider, has partnered with Solidus Labs, a pioneer in crypto-native compliance and risk management solutions, to strengthen its compliance program and ensure readiness for the European Union's upcoming Markets in Crypto-Assets Regulation (MiCA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212677489/en/
Solidus Labs enters partnership with Kairon Labs (Graphic: Business Wire)
With a proven track record of supporting over 500 digital asset issuers across more than 100 exchanges, Kairon Labs is committed to ethical market-making practices that promote transparency and fairness in the crypto space. By integrating Solidus Labs' trade surveillance technology, Kairon Labs aims to proactively monitor and mitigate market manipulation risks across its operations, reinforcing its dedication to market integrity.
"As regulatory environments become increasingly stringent, it's imperative to uphold the highest standards of compliance," said Jens Willemen, Co-Founder and CEO of Kairon Labs. "Solidus Labs has proven to be the ideal partner for us, thanks to their unmatched expertise in trade surveillance and profound comprehension of the cryptocurrency landscape, especially in the context of the Markets in Crypto-Assets (MiCA) regulation. Their advanced detection algorithms, combined with a holistic compliance platform, align seamlessly with our vision of ensuring a secure trading environment for our clients while maintaining market integrity at every level."
Solidus Labs, a trusted partner for institutions dedicated to crypto integrity, provides Kairon Labs with a robust market integrity toolkit. From real-time anomaly detection to precision-driven behavioral insights, this collaboration will enable thorough monitoring and effective detection of suspicious activities across Kairon’s operations.
"By championing transparency, innovation, and trust, Kairon Labs is shaping the future—one where markets aren’t just made—they’re made better," said Asaf Meir, CEO and Founder of Solidus Labs. "With Solidus, they’re not just prepared for MiCA—they’re setting the gold standard for safe, forward-looking market making. Together, we’re building the foundation for the financial markets of tomorrow."
With MiCA’s sweeping anti-market abuse mandates set to take effect on December 30, 2024, the timing of this collaboration couldn’t be more pivotal. Kairon Labs is demonstrating that in market making, liquidity flows to safety and that market integrity is not just a responsibility—it’s a competitive advantage.
About Kairon Labs:
Kairon Labs is a premier crypto market maker and liquidity provider, offering bespoke algorithmic trading solutions to digital asset issuers. With a focus on ethical market-making practices, Kairon Labs has supported over 500 clients, ensuring successful token launches and sustained market stability. For more information, visit: Kairon Labs
About Solidus Labs
Solidus Labs is the category-definer for crypto-native security and compliance solutions: trade surveillance, transaction monitoring, and staking guard. Solidus Labs leads initiatives like the Crypto Market Integrity Coalition and the DACOM Summit, with a commitment to safe crypto trading across centralized and decentralized markets. For more information, visit: https://soliduslabs.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212677489/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom